Filing Flows

Filing Flows › Industrials › Agilent Technologies (A)

Agilent Technologies (A) earnings and revenue breakdown

Latest: Q3 FY26 · 10-Q filed Sep 1, 2026 · Agilent Technologies (A) Q3 FY26 earnings results →

Q3 FY26 Revenue up 8% year over year to $1.9B · 19¢ of every $1 of revenue kept as net profit · operating margin 23.6%

Agilent Technologies made $1.9B in Q3 FY26 (+8% Y/Y): Agilent CrossLab $786M, Life Sciences and Diagnostics Markets $746M, Applied Markets $346M. Operating margin 23.6%, net earnings $362M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Sep 1, 2026.

Revenue$1.9B
Year over year+8%
Operating margin23.6%
Net earnings$362M
Operating cash flow$519M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

Agilent Technologies Q3 FY26 revenue breakdown: Sankey diagram of revenue (Agilent CrossLab, Life Sciences and Diagnostics Markets, Applied Markets), costs, profit and cash flow
Agilent Technologies Q3 FY26 revenue breakdown — free to use with credit and a link (terms). Share on X
Embed this chart on your site

Free to use with the credit line. Click a box to select the code.

What changed this quarter

Revenue was $1.9B in Q3 FY26, up 8% year over year and up 2% from the previous quarter. Agilent CrossLab was the largest line at 42% of revenue. Life Sciences and Diagnostics Markets added $0.08B year over year (up 11%), 54% of the total change.

Operating profit was $0.44B, a 23.6% margin (up 2.9 points year over year). Of the extra revenue versus Q3 FY25, 60% reached operating profit, above the 21% margin then. Total costs grew 4% against revenue growth of 8%. The fastest-growing cost line was SG&A (+14%). Net earnings were $0.36B, up 8% year over year. The effective tax rate was 18.5%.

Operating cash flow was $0.52B (up 43% year over year), 143% of net earnings. Non-cash charges added back $0.07B of depreciation and amortization and $0.03B of share-based compensation. Working capital and other items added $0.06B. Capital expenditures of $0.08B left free cash flow of $0.44B.

Quarterly history

Agilent Technologies revenue by quarterAgilent Technologies revenue by quarter$1.7BQ4 FY24$1.7BQ2 FY25$1.7BQ3 FY25$1.9BQ4 FY25$1.8BQ1 FY26$1.8BQ2 FY26$1.9BQ3 FY26
Agilent Technologies net earnings by quarterAgilent Technologies net earnings by quarter$351MQ4 FY24$215MQ2 FY25$336MQ3 FY25$434MQ4 FY25$305MQ1 FY26$339MQ2 FY26$362MQ3 FY26
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 FY2610-QSep 1, 2026$1.9B+8%23.6%$362M$519M
Q2 FY2610-QJun 1, 2026$1.8B+10%21.7%$339M$277M
Q1 FY2610-QMar 3, 2026$1.8B+7%19.6%$305M$268M
Q4 FY2510-KDec 22, 2025$1.9B+9%23.8%$434M$545M
Q3 FY2510-QAug 29, 2025$1.7B+10%20.7%$336M$362M
Q2 FY2510-QJun 2, 2025$1.7B+6%18.0%$215M$221M
Q4 FY2410-KDec 20, 2024$1.7B+0.8%24.0%$351M$481M

Charts

Agilent Technologies: revenue growth, year over year and quarter over quarterAgilent Technologies: revenue growth, year over year and quarter over quarterY/YQ/Q+1%Q4 FY24+6%-2%Q2 FY25+10%+4%Q3 FY25+9%+7%Q4 FY25+7%-3%Q1 FY26+10%+2%Q2 FY26+8%+2%Q3 FY26
Latest (Q3 FY26): Y/Y +8%, Q/Q +2%.
Agilent Technologies: where the cash came from (+) and went (−), TTM to Q3 FY26Agilent Technologies: where the cash came from (+) and went (−), TTM to Q3 FY26Operating cash flow$1.6BAcquisitions−$950MNet borrowing (+) / repaid (−)$540MBuybacks−$380MCapital spending−$342MDividends−$286MCash drawn (+) / kept (−)−$223MShares issued$75.0MTaxes on employees’ shares−$32.0MOther financing−$12.0MExchange rates$1.0M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Agilent Technologies: profit against cash, quarter by quarterAgilent Technologies: profit against cash, quarter by quarterNet incomeOperating cash flow$351M$481MQ4 FY24$318M$431MQ1 FY25$215M$221MQ2 FY25$336M$362MQ3 FY25$434M$545MQ4 FY25$305M$268MQ1 FY26$339M$277MQ2 FY26$362M$519MQ3 FY26
Latest (Q3 FY26): Net income $362M, Operating cash flow $519M.
Agilent Technologies: diluted shares by fiscal yearAgilent Technologies: diluted shares by fiscal year312MFY20307MFY21300MFY22296MFY23291MFY24285MFY25
-8.7% since FY20: buybacks shrank the count.
Agilent Technologies in its industry: growth against margin (23 companies, SIC 3826)Agilent Technologies in its industry: growth against margin (23 companies, SIC 3826)revenue growth, year over year →↑ operating marginmedian +6%median -11%WATAVTRILMNMTDBRKRRVTYBIOTXGCTKBPACBALMRQTRXHBIOMASSBNGORPIDPRPOSEERLCTCSCNDEYPTASTCA (+8%, 24%)
Laboratory Analytical Instruments; dot size is quarterly revenue; dashed lines are the industry's medians.

In supply chains and themes

GLP-1 & obesity drugs money flowGLP-1 & obesity drugs · Bioprocess & lab tools

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Agilent Technologies

Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy. Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment. Our chemistries and supplies, laboratory automation, and software and informatics divisions moved from our former Life Sciences and Applied Markets segment to our Agilent CrossLab segment.

In its own words, from its 10-K, filed Dec 22, 2025.

Agilent Technologies against its Laboratory Analytical Instruments peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +8% against the peers' median +4%. Operating margin: 23.6% against the peers' median 8.2%.

CompanyQuarterRevenueY/YOp. margin
A Agilent TechnologiesQ3 FY26$1.9B+8%23.6%
WAT WatersQ3 2026$1.8B+121%7.2%
AVTR AvantorQ3 2026$1.7B+5%8.2%
ILMN IlluminaQ3 2026$1.1B+4%27.0%
MTD Mettler Toledo InternationalQ3 2026$1.1B+6%27.4%
BRKR BrukerQ3 2026$874M+2%-10.4%
RVTY RevvityQ3 2026$729M+4%10.6%
BIO Bio-Rad LaboratoriesQ3 2026$656M+0.5%-7.6%
TXG 10x GenomicsQ3 2026$151M+1%-10.7%

Source: Agilent Technologies 10-Q on SEC EDGAR · CIK 1090872 · Laboratory Analytical Instruments

Guidance and outlook

Agilent Technologies Revenue: guidance against what was reportedAgilent Technologies Revenue: guidance against what was reportedguided rangereported (above / within / below)Q2 FY25$1.7BQ3 FY25$1.7BFY25$6.9BQ4 FY25$1.9BFY26Q1 FY26$1.8BQ2 FY26$1.8BQ3 FY26$1.9B
Met or beat 8 of 8 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.
Agilent Technologies GAAP net income: guidance against what was reportedAgilent Technologies GAAP net income: guidance against what was reportedguided rangereported (above / within / below)FY25$1.3BFY26
Met or beat 1 of 1 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

13F: who owns A and who is buying

Largest holders of A (13F)Largest holders of A (13F)Vanguard Group$4.6BBlackRock$3.4BVanguard Capital Management LLC$2.5BVanguard Portfolio Management LLC$1.9BState Street$1.7BMassachusetts Financial Services$1.4BDeutsche Bank Ag\$1.2BT. Rowe Price Investment Manageme…$1.0BGeode Capital Management, LLC$1.0BWellington Management Group LLP$990M
Funds' net buying of A by quarter (13F)Funds' net buying of A by quarter (13F)$268M2024-09$44.6M2024-12−$65.5M2025-03$408M2025-06−$294M2025-09$1.0B2025-12−$615M2026-03$449M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on A

History

Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results · Q4 FY24 results

Compare A with

中文版：Agilent Technologies（A）财报

Español · Français